文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

半腺体局灶低剂量率前列腺近距离放疗的剂量学结果分析

Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes.
PubMed 文献 · Radiother Oncol · 2016-11-01

这项初步研究评估了半腺体低剂量率(HG-LDR)近距离放疗作为局灶治疗控制单侧局限性前列腺癌的可行性。结果显示靶区半腺体术后D90为153.8(11.3)Gy,对侧半腺体为47.5(12.7)Gy(P<0.001),靶区V100%为93.1(3.9),对侧为24.6(10.5)(P<0.001),尿道D30在HG-LDR组为150.4(19.8)Gy,全腺体组为174.2(15.0)Gy(P<0.001),直肠和神经血管束剂量也显著降低。结论认为HG-LDR局灶近距离放疗可行,能显著降低对侧半腺体和危及器官的剂量。

要点

  • HG-LDR近距离放疗靶区半腺体D90达153.8 Gy,对侧半腺体仅47.5 Gy(P<0.001)。
  • 靶区V100%为93.1%,对侧半腺体为24.6%(P<0.001)。
  • 尿道D30在HG-LDR组为150.4 Gy,低于全腺体组的174.2 Gy(P<0.001)。

核心结论

  • HG-LDR局灶近距离放疗可行,能显著降低对侧半腺体和危及器官的剂量。

研究设计与样本

  • 采用多参数MRI和经会阴模板定位活检识别低体积单侧病变,所有植入均使用4D近距离放疗技术。

主要发现

  • 靶区半腺体术后平均D90为153.8(11.3)Gy,对侧半腺体为47.5(12.7)Gy(P<0.001)。
  • 靶区半腺体术后平均V100%为93.1(3.9),对侧半腺体为24.6(10.5)(P<0.001)。
  • 尿道D30在HG-LDR组为150.4(19.8)Gy,全腺体组为174.2(15.0)Gy(P<0.001)。
  • 直肠和神经血管束的剂量也显著降低。

关键数值与推荐

  • 术中及术后剂量学符合既定近距离放疗参数。

临床怎么用

  • 对于经多参数MRI和定位活检确认的低体积单侧局限性前列腺癌,HG-LDR可作为减少对侧腺体和危及器官剂量的局灶治疗选择。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Advances in magnetic resonance imaging (MRI) and prostate sampling enable early identification of men with low to intermediate risk prostate cancer who are candidates for focal therapies that minimise side effects. We report dosimetry data from a pilot study evaluating the effectiveness of hemi-gland low dose rate (HG-LDR) brachytherapy as a focal therapy approach to control unilateral localised disease. MATERIAL AND METHODS: Twenty-two men underwent HG-LDR brachytherapy. Multi parametric MRI and transperineal template mapping biopsies were used to identify low volume unilateral disease. Whole gland therapy controls (n=120) were retrospectively obtained. All implants were performed with 4D Brachytherapy. RESULTS: Intraoperative and postimplant dosimetry complied with established brachytherapy parameters. Mean (standard deviation) postoperative D90 for the target hemi-gland was 153.8 (11.3) Gy compared to 47.5 (12.7) Gy for the contralateral hemi-gland (P<0.001). Mean postoperative V100% was 93.1 (3.9) and 24.6 (10.5) for the target and contralateral hemi-glands respectively (P<0.001). Urethra D30 was 150.4 (19.8) Gy and 174.2 (15.0) Gy for hemi-gland and whole gland implants respectively (P<0.001). Significantly reduced dose was also observed for rectum and neurovascular bundles. CONCLUSIONS: HG-LDR focal brachytherapy is feasible with significant reduction in dose to the contralateral hemi-gland and organs at risk.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Laing R, Franklin A, Uribe J, et al. Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes. Radiother Oncol. 2016. PMID: 27814981. doi:10.1016/j.radonc.2016.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。